Vaxxinity (VAXX)
Democratizing health through technology by pioneering the third biologic revolution.
Overview
IPO Stage
Robinhood
11/11/2021
IPO
Nasdaq
$14 - $16
Equity - Common
Series A
S-1
$2B
BofA Securities, Jefferies, Evercore
0
2021
Healthcare & Pharmaceuticals
Biotech
B2B/B2C
Medium
High
Income Statement
|
Revenue |
$557,000 |
|
Operating Expenses |
|
|
Research/Technology & Development |
$20,570,000 |
|
Sales & Marketing |
$0 |
|
General & Administrative |
$12,217,000 |
|
Total Operating Expenses |
$32,787,000 |
|
Operating Income |
$-32,282,000 |
|
Other Income, Net |
$0 |
|
Income (Loss) Before Provision For (Benefit From) Income Taxes |
$-39,957,000 |
|
Provision For (Benefit From) Income Taxes |
$0 |
| Net Income (Loss) |
$-39,957,000 |
|
Net Income (Loss) Attributable to Common Stockholders: |
|
|
Basic |
$0.00 |
|
Diluted |
$0.00 |
|
Net Income (Loss) Per Share Attributable to Common Stockholders: |
|
|
Basic |
$-0.61 |
|
Diluted |
$-0.61 |
|
Weighted-Average Shares of Common Stock Used For Pro Forma: |
|
|
Basic |
65,638,946 |
|
Diluted |
65,638,946 |
Balance Sheet - Assets
|
Current Assets |
|
|
Cash and Cash Equivalents |
$31,143,000 |
|
Accounts Receivable |
$26,000 |
|
Total Current Assets |
$35,674,000 |
|
Property and Equipment, Net |
$12,158,000 |
|
Goodwill |
$0 |
|
Intangible Assets, Net |
$0 |
|
Restricted Cash |
$55,000 |
|
Other Assets |
$0 |
| Total Assets |
$50,141,000 |
Balance Sheet - Liabilities
|
Current Liabilities |
|
|
Accounts Payable |
$1,017,000 |
|
Accrued Expenses |
$610,000 |
|
Other Current Liabilities |
$0 |
|
Total Current Liabilities |
$37,224,000 |
| Total Liabilities |
$75,041,000 |
|
Commitments and Contingencies |
|
|
Convertible Preferred Stock |
$10,383,000 |
|
Stockholders' (deficit) Equity |
|
|
Common Stock |
$272,000 |
|
Additional Paid In Capital |
$4,682,000 |
|
Accumulated Other Comprehensive Income (Loss) |
$-92,306,000 |
| Total Stockholders' (Deficit) Equity |
$-87,375,000 |
Statements of Cash Flows
|
Cash Flows from Operating Activites |
|
|
Net Cash Provided By (Used In) Operating Activities |
$-33,910,000 |
|
Cash Flows from Investing Activites |
|
|
Net Cash Provided By (Used In) Investing Activities |
$-1,477,000 |
|
Cash Flows from Financing Activites |
|
|
Net Cash Provided By (Used In) Financing Activities |
$66,109,000 |
| Total Cash, Cash Equivalents, and Restricted Cash |
$0 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual